Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS

2005 ◽  
Vol 167 (1-2) ◽  
pp. 175-182 ◽  
Author(s):  
Merja Soilu-Hänninen ◽  
Mikko Laaksonen ◽  
Arno Hänninen ◽  
Juha-Pekka Erälinna ◽  
Martin Panelius
CNS Spectrums ◽  
1998 ◽  
Vol 3 (9) ◽  
pp. 64-71 ◽  
Author(s):  
Gary A. Christenson ◽  
Scott J. Crow ◽  
James E. Mitchell ◽  
Thomas B. Mackenzie ◽  
Ross D. Crosby ◽  
...  

AbstractThis short-term, open-label study investigates short- and long-term effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for the treatment of trichotillomania (TTM). Additionally, this study aimed to test the hypothesis that the presence of hair pulling compulsiveness is predictive of SSRI response. Nineteen subjects meeting the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised, (DSM-III-R) criteria for TTM were treated with fluvoxamine at doses up to 300 mg/day. Random regression analysis of change across time for patients who completed the study (n=14) and those who dropped out (n=5) revealed statistically significant improvements in Physician Rating Scale, hair-pulling episodes, Trichotillomania Impairment Scale, and Trichotillomania Symptom Severity Scale, but not in estimated amount of hair pulled. In addition, the percentage of patients' focused or compulsive hair-pulling symptoms was predictive of treatment response. Unfortunately, all three subjects who entered long-term treatment displayed substantial movement back toward baseline by the end of 6 months. We concluded that fluvoxamine produces moderate reductions in symptoms during the short-term treatment of TTM and that the presence of focused or compulsive hair pulling may be predictive of treatment response. However, responses may be short lived when treatment is extended.


2007 ◽  
Vol 13 (2) ◽  
pp. 256-259 ◽  
Author(s):  
C Papeix ◽  
J-S Vidal ◽  
J De Seze ◽  
C Pierrot-Deseilligny ◽  
A Tourbah ◽  
...  

To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P = 0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants. Multiple Sclerosis 2007; 13: 256–259. http://msj.sagepub.com


2011 ◽  
Vol 7 ◽  
pp. S665-S665
Author(s):  
Barbara Schaeuble ◽  
Maren Gaudig ◽  
Ute Richarz ◽  
Shane Kavanagh ◽  
Bart Van Baelen

Sign in / Sign up

Export Citation Format

Share Document